Redefining fatty liver disease: an international patient perspective.

Shiha, Gamal; Korenjak, Marko; Eskridge, Wayne; Casanovas, Teresa; Velez-Moller, Patricia; Högström, Sari; Richardson, Ben; Munoz, Christopher; Sigurðardóttir, Sólveig; Coulibaly, Alioune; Milan, Miskovikj; Bautista, Fabiana; Leung, Nancy Wai Yee; Mooney, Vicki; Obekpa, Solomon; Bech, Eva; Polavarapu, Naveen; Hamed, Abd Elkhalek; Radiani, Temur; Purwanto, Edhie; ... (2021). Redefining fatty liver disease: an international patient perspective. The lancet. Gastroenterology & hepatology, 6(1), pp. 73-79. Elsevier 10.1016/S2468-1253(20)30294-6

[img] Text
1-s2.0-S2468125320302946-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (955kB) | Request a copy

Despite its increased recognition as a major health threat, fatty liver disease associated with metabolic dysfunction remains largely underdiagnosed and undertreated. An international consensus panel has called for the disease to be renamed from non-alcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD) and has suggested how the disease should be diagnosed. This Viewpoint explores the call from the perspective of patient advocacy groups. Patients are well aware of the negative consequences of the NAFLD acronym. This advocacy group enthusiastically endorses the call to reframe the disease, which we believe will ultimately have a positive effect on patient care and quality of life and, through this effect, will reduce the burden on health-care systems. For patients, policy makers, health planners, donors, and non-hepatologists, the new acronym MAFLD is clear, squarely placing the disease as a manifestation of metabolic dysfunction and improving understanding at a public health and patient level. The authors from representative patient groups are supportive of this change, particularly as the new acronym is meaningful to all citizens as well as governments and policy makers, and, above all, is devoid of any stigma.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Hepatology
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie

UniBE Contributor:

Dufour, Jean-François

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2468-1253

Publisher:

Elsevier

Language:

English

Submitter:

Thi Thao Anh Pham

Date Deposited:

09 Dec 2020 08:22

Last Modified:

16 Dec 2020 01:33

Publisher DOI:

10.1016/S2468-1253(20)30294-6

PubMed ID:

33031758

BORIS DOI:

10.7892/boris.148102

URI:

https://boris.unibe.ch/id/eprint/148102

Actions (login required)

Edit item Edit item
Provide Feedback